CST, 47369SF, CD22 (F9D1W) Rabbit Monoclonal Antibody (BSA and Azide Free)

Monoclonal Antibody for studying CD22 mouse. Validated for WB,IHC,IHC,IF. Highly specific and rigorously validated in-house, CD22 (F9D1W) Rabbit Monoclonal Antibody (BSA and Azide Free) (CST #47369) is ready to ship. Product Usage Information This product is the carrier free version of product #94346. All data were generated using the same antibody clone in the standard formulation which contains BSA and glycerol. This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us . Optimal dilutions/concentrations should be determined by the end user. BSA and Azide Free antibodies are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity. Formulation Supplied in 1X PBS (10 mM Na 2 HPO 4 , 3 mM KCl, 2 mM KH 2 PO 4 , and 140 mM NaCl (pH 7.8)). BSA and Azide Free. For standard formulation of this product see product # 94346 Storage Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. Specificity / Sensitivity CD22 (F9D1W) Rabbit Monoclonal Antibody (BSA and Azide Free) recognizes endogenous levels of total CD22 protein. Species Reactivity: Mouse Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser467 of mouse CD22 protein. Background CD22 (also known as siglec-2) is a member of the sialic acid-binding immunoglobulin-type lectin (Siglec) family of immunomodulatory receptors. CD22 can bind to its ligand α 2,6-linked sialic acid on different cells (trans interaction) as well as on the same cells (cis interaction). CD22 is predominantly expressed on B cells and functions as an inhibitory co-receptor for the B cell receptor (BCR) (1,2). After BCR ligation, the tyrosine kinase Lyn is activated and phosphorylates two distal of the four ITIM motifs in the intracellular carboxy-terminal region of CD22, which then recruit tyrosine phosphatases, including SHP-1, to the plasma membrane, and in turn, they get tyrosine-phosphorylated and activated to damp the signaling pathways initiated by BCR ligation (3,4). CD22 has been actively pursued as a therapeutic target for autoimmune diseases (5). Due to almost exclusive expression on B cells, it is also actively pursued as a therapeutic target for multiple B cell malignancies (6-8). Alternate Names A530093D23; B-cell receptor CD22; B-lymphocyte cell adhesion molecule; BL-CAM; Cd22; CD22 antigen; Lyb; Lyb-; Lyb-8; Lyb8; Sialic acid-binding Ig-like lectin 2; Siglec-2; Siglec2; T-cell surface antigen Leu-14 Specification REACTIVITY: M SENSITIVITY: Endogenous MW (kDa): 140 Source/Isotype: Rabbit IgG